Gastrointestinal Cancer | Norton Healthcare

Indication: Gastrointestinal Cancer

A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

Sub-indication: Hepatocellular Carcinoma

Line of Therapy: 1st line

Drug Study

Principal Investigator: Michael Driscoll, M.D.
Norton Cancer Institute

Sponsor: Bristol-Myers Squibb (BMS)

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.